Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01738646 · ClinicalTrials.gov registry record · Phase 2
Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients
A Phase 2 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
NCT01738646 is a Phase 2 study that has completed, run by Duke University. The registered enrollment target is 48 participants.
The verdict
NCT01738646, a Phase 2 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
Study Summary
It has been shown that bevacizumab has significant anti-tumor activity in patients with recurrent glioblastoma multiforme. Vorinostat has modest anti-tumor activity against malignant glioma and can enhance the action of both chemotherapy and anti-angiogenics. Patients will be treated with a combination of bevacizumab and vorinostat.
Interventions
- DRUG Bevacizumab
- DRUG Vorinostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2013-01 |
| Est. Completion | 2016-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01738646
The ClinicalTrials.gov registry entry for NCT01738646 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bevacizumab is the first listed.
NCT01738646 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01738646 about?
NCT01738646 is a clinical study titled "Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients". It has been shown that bevacizumab has significant anti-tumor activity in patients with recurrent glioblastoma multiforme. Vorinostat has modest anti-tumor activity against malignant glioma and can enhance the action of both chemotherapy and anti-angiogenics. Patients will be treated with a combinat...
What is the current status of trial NCT01738646?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2013-01. Estimated completion is 2016-02.
What interventions are being tested in trial NCT01738646?
The interventions under investigation include: Bevacizumab (DRUG), Vorinostat (DRUG).
Who is sponsoring clinical trial NCT01738646?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.